

Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study

Hildegard T. Greinix,¹ Dirk-Jan Eikema,² Linda Koster,³ Olaf Penack,⁴ Ibrahim Yakoub-Agha,⁵ Silvia Montoto,⁶ Christian Chabannon,⁷ Jan Styczynski,⁸ Arnon Nagler,⁹ Marie Robin,¹⁰ Stephen Robinson,¹¹ Yves Chalandon,¹² Malgorzata Mikulska,¹³ Stefan Schönland,¹⁴ Zinaida Peric,¹⁵ Annalisa Ruggeri,¹⁶ Francesco Lanza,¹⁷ Liesbeth C. de Wreede,¹⁸ Mohamad Mohty,¹⁹ Grzegorz W. Basak²⁰ and Nicolaus Kröger²¹

¹Department of Medicine, Division of Haematology, Medical University of Graz, Graz, Austria; ²EBMT Statistical Unit, Leiden, the Netherlands; ³EBMT Data Office Leiden, Leiden, the Netherlands; ⁴Medical Department of Hematology, Oncology and Tumor Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany; ⁵Department of Haematology, CHU de Lille, University Lille, INSERM U1286, Infnite, Lille, France; ⁶St. Bartholomew's hospital, Barts Health NHS Trust, London, UK; ⁷Institut Paoli Calmettes, Marseille, France; ⁸Collegium Medicum, Nicolaus Copernicus University Torun, Bydgoszcz, Poland; ⁹Hematology and BMT Division, Chaim Sheba Medical Center, Tel-Hashomer, Tel-Aviv University, Ramat-Gan, Israel; ¹⁰Hematology / Transplantation, Hôpital Saint-Louis, Paris Cedex 10, France; ¹¹Bristol Oncology Centre, Bristol, UK; ¹²Département d'Oncologie, Service d'Hématologie, Hôpitaux Universitaires de Genève and Faculty of Medicine, University of Geneva, Geneva, Switzerland; ¹³Division of Infectious Diseases, University of Genova, Ospedale Policlinico San Martino, Genova, Italy; ¹⁴University Hospital of Heidelberg, Heidelberg, Germany; ¹⁵University Hospital Center Rebro, Zagreb, Croatia; ¹⁶Hematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy; ¹⁷Ravenna Hospital, Ravenna, Italy; ¹⁸Department of Biomedical Data Sciences, LUMC Leiden, Leiden, the Netherlands; ¹⁹Hopital Saint Antoine, Paris Cedex 12, Paris, France; ²⁰Department of Hematology, Oncology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland and ²¹University Hospital Eppendorf, Hamburg, Germany

©2022 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2020.265769

Received: July 3, 2020.

Accepted: June 11, 2021.

Pre-published: June 24, 2021.

Correspondence: *HILDEGARD GREINIX* - hildegard.greinix@medunigraz.at

Supplementary Table 1. Characteristics of acute GvHD.

	Year of transplant										P-Value
	1990-1995		1996-2000		2001-2005		2006-2010		2011-2015		
Acute GvHD Grade	Probability %	95% CI %	Probability %	95% CI %	Probability %	95% CI %	Probability %	95% CI %	Probability %	95% CI %	
Day 100, Grades II-IV	40	38-42	38	37-39	32	31-33	29	28-29	28	27-28	<0.001
Day 100, Grade II	21	20-23	22	21-22	19	18-19	17	17-18	17	17-17	<0.001
Day 100, Grade III	11	10-12	10	9-10	8	8-9	7	7-8	7	7-7	
Day 100, Grade IV	8	7-9	7	6-7	5	5-5	4	4-4	4	4-4	

Abbreviations: GvHD=graft-versus-host disease; CI=confidence interval.

Supplementary Table 2. Causes of death.

	Group	Total		1990-1995	1996-2000	2001-2005	2006-2010	2011-2015	
		Missing	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	
Cause of Death	Primary disease	1378 (3.2 %)	16590 (39.9 %)	452 (25.9 %)	1481 (33.7 %)	3756 (43 %)	5333 (42.2 %)	5568 (39.6 %)	
	GvHD		8946 (21.5 %)	506 (29 %)	1009 (23 %)	1739 (19.9 %)	2672 (21.1 %)	3020 (21.5 %)	
	Infection		9427 (22.7 %)	523 (30 %)	1090 (24.8 %)	1847 (21.1 %)	2682 (21.2 %)	3285 (23.4 %)	
	Organ failure		2837 (6.8 %)	154 (8.8 %)	326 (7.4 %)	599 (6.9 %)	796 (6.3 %)	962 (6.8 %)	
	Other		3757 (9 %)	108 (6.2 %)	484 (11 %)	794 (9.1 %)	1161 (9.2 %)	1210 (8.6 %)	

Abbreviations: N=number; GvHD=graft-versus-host disease.